Related Experiment Videos
[Antiplatelet therapy in cardiac diseases]
Insights
Aspirin therapy effectively reduces mortality and reinfarction in myocardial infarction and unstable angina. It is also recommended for preventing complications after coronary artery bypass grafting and percutaneous transluminal coronary angioplasty.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Medicine
Context:
- Aspirin is a widely used antiplatelet medication.
- Cardiovascular diseases remain a leading cause of mortality worldwide.
- Understanding the efficacy of aspirin in various cardiovascular conditions is crucial for clinical practice.
Purpose:
- To summarize the established role of aspirin in managing myocardial infarction (MI), angina pectoris, and post-procedural care for coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA).
Summary:
- Aspirin (160-300 mg/day) initiated immediately post-myocardial infarction (MI) reduces mortality and reinfarction, with maintenance therapy recommended.
- For unstable angina, aspirin (300 mg/day for 2 years) lowers mortality and MI incidence; ticlopidine shows some benefit for angina at rest.
- Post-CABG, aspirin (325 mg/day) combined with dipyridamole is advised. For PTCA, antiplatelet drugs prevent acute occlusion but not late restenosis.
Impact:
- This information supports the use of aspirin as a cornerstone therapy in preventing thrombotic events across a spectrum of cardiovascular conditions.
- Optimized aspirin regimens can improve patient outcomes and reduce the risk of recurrent cardiovascular events.
- Further research may explore novel antiplatelet strategies for conditions like late restenosis post-PTCA.
Abstract:
1) Myocardial infarction (MI): Aspirin (160-300 mg/day) therapy started immediately after the onset, with or without simultaneous coronary arterial thrombolytic therapy, reduces the mortality rate in vascular diseases, including MI, and prevents reinfarction. Maintenance therapy with the same dosage is also recommended. 2) Angina pectoris: In unstable angina, aspirin in a dose of 300 mg/day for 2 years reduces the mortality and the incidence of MI. Ticlopidine decreases anginal attacks in a few cases of angina at rest. 3) Coronary artery bypass grafting (CABG): Long-term administration of 325 mg aspirin/day should be started on the day of surgery and combined with 200-400 mg dipyridamole/day administered from 2 days before to 1 week after the surgery. 4) Percutaneous transluminal coronary angioplasty (PTCA): Current antiplatelet drugs prevent post-procedural acute coronary occlusion but not late restenosis.